Legal Representation
Attorney
Jeffrey L. Costellia
USPTO Deadlines
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 22, 2018 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Jan 22, 2018 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Jun 26, 2017 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jun 26, 2017 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Jun 26, 2017 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Jun 3, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 1, 2017 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 1, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 1, 2016 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 1, 2016 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 1, 2016 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 10, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 9, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 9, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 10, 2016 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 10, 2016 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 10, 2016 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 4, 2016 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 26, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 23, 2016 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for protection against free radicals; pharmaceutical preparations for removing free radicals from the human bodies; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS); neuroprotective medicines; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; antiallergic medicines; antihypertensives; hypoglycemic agents; antidiabetic preparations; pharmaceutical preparations for the prevention of diabetic nephropathy; pharmaceutical preparations, namely, antiphlogistic agents; vaccine; pharmaceutical preparations for the treatment of autoimmune disease; pharmaceutical preparations for the treatment of cerebral infarction; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of erectile dysfunction
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMA"